

Câncer de Glândula Salivar

Adriamicina + Cisplatina

Adriamicina: 50mg/m² IV D1

Cisplatina: 20mg/m²/dia IV D1 a D5
a cada 3 semanas

Ref. (1)

Paclitaxel + Carboplatina

Paclitaxel: 175mg/m² IV D1

Carboplatina: AUC 5 IV D1

a cada 21 dias

Ref. (2)

Ciclofosfamida

Ciclofosfamida: 1000mg/m² IV D1

a cada 21 dias

Ref.(3)

CAP

Ciclofosfamida: 500mg/m² IV D1

Doxorrubicina: 50mg/m² IV D1

Cisplatina: 50mg/m² IV D1

a cada 28 dias

Ref. (4)

PAF

Cisplatina: 50mg/m² IV D1 e D8

Doxorrubicina: 30mg/m² IV D1 e D8

5-Fluorouracil: 500mg/m² IV D1 e D8

a cada 28 dias

Ref. (5)

Epirrubicina

Epirrubicina: 90mg/m² IV D1

a cada 21 dias

Ref. (6)

Cisplatina + Vinorelbina

Cisplatina: 80mg/m² IV D1

Vinorelbina: 25mg/m² IV D1 e D8

a cada 3 semanas

Ref. (7)

1. de Haan LD, De Mulder PH, Vermorken JB, Schornagel JH, Vermey A, Verweij J. Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. *Head Neck*. 1992 Jul-Aug;14(4):273-7.
2. Airoldi M, Fornari G, Pedani F, Marchionatti S, Gabriele P, Succo G, Bumma C. Paclitaxel and carboplatin for recurrent salivary gland malignancies. *Anticancer Res*. 2000 Sep-Oct;20(5C):3781-3.
3. Spiers A, Esseltine DLW, *et al*. Metastatic Adenoid Cystic Carcinoma of Salivary Glands: Case Reports and Review of the Literature. *Cancer Control Journal*. Vol 3, No. 4 July/August 1996.
4. Dreyfuss AI, Clark JR *et al*. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. *Cancer*. 60:2869-2872, 1987.
5. Venook AP, Tseng A, *et al*. Cisplatin, Doxorubicin, and 5-Fluorouracil Chemotherapy for Salivary Gland Malignancies: A Pilot Study of the Northern California Oncology Group. *JCO* June 1, 1987 vol. 5 no. 6 951-955
6. Vermorken JB, Verweij J *et al*. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: A phase II study of the EORTC Head and Neck Cancer Cooperative Group . *Annals of Oncology* Volume4, Issue 9 Pp. 785-788.
7. Airoldi M, Pedani F, Succo G *et al*. Phase II Randomized Trial Comparing Vinorelbine versus Vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. *Cancer* 2001; 91: 541-7.